Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Leukemia. 2013 Jul 1;27(12):2272–2279. doi: 10.1038/leu.2013.197

Figure 4. TG101209 caused a modest but significant decrease in hemoglobin and hematocrit levels in MigR1 control mice.

Figure 4

Percentages of EGFP+ cells (A) and white blood cell (WBC) counts (B) in the peripheral blood of MigR1 transplanted mice before and after treatment with placebo or TG101209 (100 mg/kg, twice daily) for one or two weeks. Horizontal bars indicate the mean values. (C) Comparisons of hemoglobin (Hb) concentrations and hematocrit (HCT) levels in the peripheral blood of MigR1 mice treated with placebo or TG101209 for one or two weeks. The p values were determined using Student’s t-test.